宝宝树集团(01761.HK)拟向小星医生增资400万元
格隆汇7月15日丨宝宝树集团(01761.HK)发布公告,2019年5月28日,公司间接全资附属公司海囤国际与复星医药(600196.SH)及复星医药间接附属公司万邦云健康订立股权转让协议,据此,海囤国际将以代价270万元人民币(下同)向复星医药收购小星医生15%股权,并以代价90万元向万邦云健康收购小星医生的5%股权。
代价已于2019年6月14日以现金结清,收购完成后,小星医生由海囤国际、复星医药及复星国际(00656.HK)间接全资附属公司复星健康分别拥有50%、10%及40%。
2019年7月15日,海囤国际与复星医药及复星健康订立增资协议,据此,订约方同意将小星医生的注册资本由1800万元增至2600万元,并按各自于小星医生的持股比例为增资出资。因此,海囤国际、复星医药及复星健康将分别就小星医生的注册资本出资400万元、80万元及320万元。
小星医生是一家于2018年7月11日在中国注册成立的有限责任合营公司。小星医生致力于为年轻家庭提供专业医疗及健康服务,特别是在其初生婴儿出生后的头一千天。
紧接股权收购完成前,小星医生由海囤国际、复星医药、复星健康及万邦云健康分别拥有30%、25%、40%及5%,上述各方均已按其各自的持股比例就小星医生的注册资本出资。股权收购完成后,小星医生由海囤国际、复星医药及复星健康分别拥有50%、10%及40%。股权收购将不会导致小星医生被视为公司的附属公司,亦不会导致将小星医生的资产综合并入公司账目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.